Hims has added injectable and oral TRT options. A closer look at screening, FDA status, fertility concerns and the limits of the launch announcement.
On October 21, 2026, Hims & Hers Health announced three testosterone-replacement options for eligible men: two injectable options and one oral option. The longer product list makes one word in the announcement especially important: “eligible.”
Hims described the launch as its largest men’s-health expansion since entering the category the previous September. According to the company, prescribing follows a review of symptoms and risk factors alongside laboratory testing and a live provider visit. For readers noticing changes in energy or sexual wellbeing, the news concerns additional treatment options rather than a new basis for self-diagnosis.
Hims’ announcement describes a commercial care pathway rather than a clinical trial. Its stated population is men whom a licensed provider considers medically appropriate for treatment.
The company says the process includes:
Hims says testing includes total and free testosterone plus SHBG. It also lists an advanced lipid panel and glycemic markers.
Treatment customers receive follow-up testing and ongoing assessments, according to the company. Hims says labs and a prescription are required and the program is not available in all 50 states.
The release also reports a company-commissioned survey of 2,000 U.S. men about their priorities and treatment awareness.
The new options listed in the company announcement are:
Hims explicitly states that compounded drug products are not FDA-approved or evaluated by the agency for safety, effectiveness or quality.
These are different regulatory categories. The oral product’s approval status should not be read as applying to every option in the announcement. A broader product range also does not establish which formulation is appropriate for an individual.
Separately, Hims says 79% of its survey respondents prioritised more energy over more muscle.
The announcement does not provide an independent assessment of its screening process or patient outcomes. It also does not set out detailed diagnostic criteria, specific contraindications or a complete list of treatment risks. The company-commissioned survey reports preferences rather than diagnoses or treatment outcomes.
Hims lists lower energy and lower sex drive among effects associated with low testosterone. The material does not establish those experiences as specific signs of testosterone deficiency.
That distinction matters when separating sexual symptoms from a diagnosis. A reported change deserves context rather than an automatic hormonal explanation.
The additions extend a program that already included Testosterone Rx+, which Hims says includes enclomiphene. Hims’ men’s-health leadership described supporting the body’s own testosterone production and replacing testosterone directly as different approaches.
The expanded offering sits alongside a clinical caution reported in coverage of the launch. Urologist Mohit Khera warned that testosterone therapy can cause infertility and is not appropriate for someone trying to conceive.
His comment makes fertility goals an important part of clinical discussion, rather than a detail to consider after choosing a product.
For readers considering what the announcement means for them, useful discussion points with a licensed clinician include:
These questions keep the discussion centred on the person rather than the format of a medicine. Readers unsure where to start can learn about finding appropriate professional support for sexual-health concerns.
The launch changes the list of products Hims offers. It does not make the opening announcement’s word “eligible” any less important.
An expanded testosterone menu brings more product choices without settling the personal questions about eligibility and future fertility. Sexential publishes evidence-aware information about hormones and sexual function for adults aged 35 to 65, connecting biological explanations with everyday concerns without offering personalised medical advice.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
A hip-fracture study linked vaginal estrogen with perioperative UTIs. Understand the findings, infection-history differences and questions for clinical care.
A report on a student survey links attention with men’s sexual satisfaction. Here’s the evidence, its limits and the practical context for midlife.
A new report puts men’s midlife testosterone changes in context, with guidance on assessment, partner conversations and fertility considerations.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
